1228 — Canbridge Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- HK$131.61m
- HK$246.40m
- CNY102.87m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.47 | 12 | 31.2 | 79 | 103 |
Cost of Revenue | |||||
Gross Profit | 0.965 | 6.88 | 18.8 | 48.9 | 64.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 217 | 854 | 1,105 | 556 | 473 |
Operating Profit | -215 | -842 | -1,074 | -477 | -370 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -218 | -846 | -1,077 | -483 | -379 |
Provision for Income Taxes | |||||
Net Income After Taxes | -218 | -846 | -1,077 | -483 | -379 |
Net Income Before Extraordinary Items | |||||
Net Income | -218 | -846 | -1,077 | -483 | -379 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -218 | -846 | -1,077 | -483 | -379 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.513 | -1.98 | -2.49 | -1.14 | -0.893 |